John Chiorini, Ph.D.

John Chiorini, Ph.D.

Acting Deputy Scientific Director, Scientific Resources

Building 10, Room 1N113
10 Center Dr. MSC 1190
Bethesda, MD 20892-1190
United States

Research Interests

Adeno-associated virus (AAV) vectors have several characteristics that make them attractive agents for gene therapy, including stability, ease of manipulation, low immunogenicity, and the ability to direct long term expression of transgenes. The overall research goal of Dr. Chiorini’s AAV Biology Section is to define the interactions of AAV with its target cell. By understanding these interactions and the biology of the virus, vectors with enhanced activity can be developed and existing vectors can be more finely targeted to specific applications.

Ongoing projects are looking at possibilities to use these vectors to treat diseases with unmet clinical need. Of special interest, are vectors that can target diseases of the salivary gland including radiation induced xerostomia and Sjögren's disease. In addition to developing gene therapy vectors targeted to the salivary gland, research projects investigate the etiology and epigenetic regulation of salivary gland dysfunction.

Biographical Sketch

Dr. John (Jay) Chiorini received a B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, and a Ph.D. in genetics from George Washington University. Dr. Chiorini completed post-doctoral training fellowships at both the National Institutes of General Medical Science (NIGMS) in the pharmacology research and training program, and at the National Heart, Lung, and Blood Institute (NHLBI) at NIH. As a postdoctoral fellow, Dr. Chiorini’s research focused on the role of the Rep proteins in AAV replication and the virus lifecycle. He cloned some of the first non-AAV2 serotypes including AAV4 and AAV5. Dr. Chiorini joined the NIDCR in 1999 and currently serves as chief of the Adeno-Associated Virus Biology Section. Findings from the group’s research are in clinical development and early stage clinical trials at the NIH and around the world.

Selected Publications
Last Reviewed on
June 2024